However, patients with advanced or metastatic BLCA ineligible for cisplatin only showed an objective remission rate (ORR) of 23%, and the median OS was 15.9 months after receiving the PD-L1 inhibitor atezolizumab as treatment in a phase II trial (Balar et al., 2017). The gene discussed is CD274; the disease is bladder transitional cell carcinoma.